Patent intelligence · US
US 10301248
Compositions and methods comprising resveratrol
Compositions and methods comprising resveratrol
Patent details — US 10301248
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 28, 2019
- Expiration
- May 23, 2039
- Applicant
- Biocogent, LLC
- Claims
- 9
- CPC classes
- A61K, A61K2800/10, A61K31/618, A61K8/37
Quick answer
US 10301248 (Compositions and methods comprising resveratrol) is held by Biocogent, LLC. Status: granted. Granted May 28, 2019. Expires May 23, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Biocogent, LLC
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61K, A61K2800/10, A61K31/618, A61K8/37
More from Biocogent, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12351581
Compounds for FGFR inhibition
granted -
US 12281122
PI3K inhibitors
granted -
US 11718576
Compositions and methods comprising resveratrol
granted -
US 11339112
Compositions and methods comprising resveratrol
granted -
US 10836702
Compositions and methods comprising resveratrol
granted -
US 10449129
Encapsulates of salicylic acid and polysalicylic acid derivatives
granted -
US 6610295
Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor
expired
Frequently asked questions
What is US patent 10301248?
US 10301248 (Compositions and methods comprising resveratrol) is held by Biocogent, LLC. Status: granted. Granted May 28, 2019. Expires May 23, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10301248?
Biocogent, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 10 pharmaceutical patents for this assignee.
When does US 10301248 expire?
Our index shows an expiration date of May 23, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.